Data from Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer

Abstract

<div>Abstract<p>Genomic analysis has recently identified multiple <i>ESR1</i> gene translocations in estrogen receptor alpha–positive (ERα<sup>+</sup>) metastatic breast cancer (MBC) that encode chimeric proteins whereby the ESR1 ligand binding domain (LBD) is replaced by C-terminal sequences from many different gene partners. Here we functionally screened 15 ESR1 fusions and identified 10 that promoted estradiol-independent cell growth, motility, invasion, epithelial-to-mesenchymal transition, and resistance to fulvestrant. RNA sequencing identified a gene expression pattern specific to functionally active ESR1 gene fusions that was subsequently reduced to a diagnostic 24-gene signature. This signature was further examined in 20 ERα<sup>+</sup> patient-derived xenografts and in 55 ERα<sup>+</sup> MBC samples. The 24-gene signature successfully identified cases harboring <i>ESR1</i> gene fusions and also accurately diagnosed the presence of activating <i>ESR1</i> LBD point mutations. Therefore, the 24-gene signature represents an efficient approach to screening samples for the presence of diverse somatic <i>ESR1</i> mutations and translocations that drive endocrine treatment failure in MBC.</p>Significance:<p>This study identifies a gene signature diagnostic for functional ESR1 fusions that drive poor outcome in advanced breast cancer, which could also help guide precision medicine approaches in patients harboring <i>ESR1</i> mutations.</p></div>